



Journal of Contemporary Neurology

VOLUME 1996, ARTICLE 1
22 MARCH 1996

ISSN 1081-1818. MIT Press Journals, 55 Hayward St., Cambridge, MA 02142, USA; (617) 253-2889; journals-orders@mit.edu, journals-info@mit.edu. Published one article at a time in Postscript and PDF source form on the Internet. For more information and other articles see:

- <http://mitpress.mit.edu/jrnls-catalog/cont-neuro.html>
- gopher.mit.edu
- anonymous ftp at mitpress.mit.edu

©1996 Massachusetts Institute of Technology. Subscribers are licensed to use journal articles in a variety of ways, limited only as required to insure fair attribution to authors and the *Journal*, and to prohibit use in a competing commercial product. See the *Journal's* World Wide Web site for further details. Address inquiries to the Subsidiary Rights Manager, MIT Press Journals; (617) 253-2864; journals-rights@mit.edu.

The MIT Press

SCOTT D. Z. EGGERS*

ANTHONY J. WINDEBANK, MD⁺

From *Mayo Medical School and the
⁺Department of Neurology, Mayo
Clinic and Mayo Foundation,
Rochester, MN 55905 USA.

Epstein-Barr Virus Transformation Induces Expression of *trk b* mRNA in Human B Lymphocytes

■ Neurotrophins may play a role in immune function modulation. We have shown that Epstein-Barr virus (EBV)-transformed B lymphocytes express functional Trk B, the high-affinity transmembrane tyrosine kinase receptor for brain-derived neurotrophic factor and neurotrophin-4/5. In this study, we have used reverse transcriptase polymerase chain reaction to examine the expression of *trk b* mRNA in normal human and EBV-transformed B lymphocytes. We demonstrated that *trk b* mRNA was undetectable in normal B lymphocytes but was expressed following EBV transformation. Additionally, normal B lymphocytes up-regulated *trk b* transcription after stimulation with a combination of B cell-specific polyclonal activating agents. ■

Keywords: CD40, RT-PCR, BDNF, NT-4/5

Neurotrophins are soluble extracellular macromolecules that promote growth, survival, and differentiation of neurons and exert their effects via cell-surface receptors. The neurotrophins include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5) (Korsching, 1993). Trk B, a member of the neurotrophin receptor family, is a transmembrane tyrosine kinase (*trk*) that binds with high affinity to BDNF and NT-4/5 (Meakin Shooter, 1992; Barbacid, 1994).

It has been proposed that neurotrophins play a role in modulating the immune response (Otten et al, 1989; Ehrhard et al, 1993). In a previous report, we demonstrated the presence of Trk B receptors on Epstein-Barr virus (EBV)-transformed human B lymphocytes and the subsequent tyrosine phosphorylation of Trk B on these cells following treatment with physiologic concentrations of BDNF (Schenone et al, 1996). Given this, it was of interest to determine whether Trk B is present on normal resting B lymphocytes or whether its expression is induced on transformation or stimulation. We used reverse transcriptase polymerase chain reaction (RT-PCR) to examine four samples of highly purified human B lymphocytes, isolated from peripheral blood, before and after EBV transformation for the presence of *trk b* mRNA transcript. Our results showed that in all samples, *trk b* mRNA was undetectable in resting B lymphocytes but was expressed following EBV transformation.

MATERIALS AND METHODS

Cell preparation and culture

One unit of heparinized venous blood was obtained from each of four healthy adult volunteers. From each sample, 10 mL were diluted 1:1 in RPMI 1640 medium (GIBCO BRL, Gaithersburg, MD) and centrifuged over Ficoll-Paque (Pharmacia Biotech, Piscataway, NJ) gradient. Permanent EBV transformation of unfractionated mononuclear leukocytes was performed as previously described (Neitzel, 1986).

Peripheral blood mononuclear cells (PBMCs) were obtained from the remainder of the volunteer samples by centrifugation over sodium diatrizoate/Ficoll gradients (Isolymp; Gallard-Schlesinger Corp., Carle Place, NY). Cells were washed three times in sterile saline prior to additional separation. Unless noted, cells were suspended in complete media, which consisted of RPMI 1640 medium (GIBCO), supplemented with gentamicin (50 µg/mL), L-glutamine (0.3 mg/mL), penicillin G (50 U/mL), streptomycin (50 µg/mL), and 10% fetal bovine serum (Intergen Company, Purchase, NY). PBMCs were separated into B cell-enriched fractions, as previously described (Rosenberg Lipsky, 1979). Briefly, PBMCs were depleted of monocytes and natural killer cells by incubating with 5 mM L-leucine methyl ester (Sigma, St. Louis, MO) in

Address reprint requests and correspondence to Anthony J. Windebank, MD, Mayo Clinic, 1501 Guggenheim Building, 200 First Street SW, Rochester, MN 55905 USA.

E-Mail: windebank.anthony@mayo.edu;
Phone (507) 284-1781; Fax (507) 284-3383.

© 1996 Massachusetts Institute of Technology

serum-free medium (Thiele et al, 1983). After washing, B cells were depleted of T cells by incubating with neuraminidase-treated sheep red blood cells (N-SRBCs) (Galili Schlesinger, 1974). The rosetting and nonrosetting populations were separated by centrifugation on diatrizoate/Ficoll gradients. The non-rosetting cells obtained from the interface were again rosetted with N-SRBCs and centrifuged on diatrizoate/Ficoll gradients to remove residual T cells. B cells prepared in this fashion are more than 90% CD20-positive, as has been previously established (Jelinek Lipsky, 1985). Human dorsal root ganglia (DRGs, collected within 12 hours of death, immediately frozen in liquid nitrogen, and stored at -70°C until used) were used as controls.

Reverse Transcriptase Polymerase Chain Reaction

Total RNA was isolated from volunteers' resting B lymphocytes and corresponding EBV-transformed B lymphocytes by a single-step method (RNA STAT-60, Tel-Test "B" Inc., Friendswood, TX). RNA was quantitated by spectrophotometry at 260 nm, and its integrity was tested by formaldehyde/agarose gel electrophoresis. First-strand cDNA was synthesized from 2 μg of total RNA in a 20 μL RT reaction containing 5 mM MgCl_2 , 1 \times PCR buffer, 2.5 μM random hexamers (Perkin-Elmer Co., Norwalk, CT), 1 U/ μL RNase inhibitor (Boehringer Mannheim Co., Indianapolis, IN), 1 mM dNTPs, and 2.5 U/ μL Moloney Murine Leukemia Virus RT (GIBCO). Polymerase chain reaction was performed in a 50- μL reaction containing 10 μL of the RT reaction, 1 \times PCR buffer, 2.5 mM dNTPs, 0.15 μM each 5' and 3' primers, and 1.25 U/50 μL of Taq DNA polymerase (Boehringer Mannheim). Amplification was performed for 35 cycles consisting of 1 minute of denaturation at 95°C , 2 minutes of annealing at 54°C , and 3 minutes of extension at 72°C , with a final extension time of 7 minutes at 72°C .

The primers specific for *trk b* have been previously described, and sequence homology of PCR products with published sequences have been verified (Schenone et al, 1996). The 518-bp amplified products were analyzed on ethidium bromide-stained 2.0% agarose gels. Primers specific for β -actin (Forward-GACTTCGAGCAAGAGATGGCCAC; Reverse-CAATGCCAGGGTACATGGTGGTG) were used as a positive control to ensure that equivalent amounts of cDNA were loaded into each PCR.


RESULTS

Reverse transcriptase polymerase chain reaction on human DRGs with primers specific for *trk b* gave the expected size, 518 bp (data not shown). Purified resting B lymphocytes from each of the four volunteers did not express mRNA for *trk b* (Fig. 1: lanes 2, 5, 8, and 11). On EBV transformation, parallel samples demonstrated PCR products of the expected size for *trk b* (see Fig. 1: lanes 3, 6, 9, and 12). β -actin mRNA expression was used to ensure that equivalent amounts of cDNA were loaded in the PCR reactions (see Fig. 1). Stimulation of untransformed B lymphocytes with a combination of CD40 ligand (CD40L), interleukin 2 (IL2), and interleukin 4 (IL4) also induced low-level *trk b* expression.

DISCUSSION

This study demonstrates that resting human B lymphocytes isolated from peripheral blood do not express detectable levels of *trk b* mRNA; EBV transformation of parallel same donor samples, however, is sufficient to induce *trk b* mRNA expression. We have shown previously that this mRNA induction translates into a functional Trk B receptor that is tyrosine phosphorylated on exposure to BDNF (Schenone et al, 1996). Because EBV infection acts as a mitogenic stimulus in B lymphocytes (Klein, 1994), our results are consistent with the notion that *trk b* up-regulation

FIGURE 1. RT-PCR amplification of *trk b* receptor mRNA before and after EBV transformation. None of four samples of purified normal B lymphocytes expressed detectable *trk b* mRNA (lanes 2, 5, 8, and 11). After EBV transformation, parallel samples from the same donor demonstrated PCR products of the expected size for *trk b* (lanes 3, 6, 9, and 12). β -actin mRNA expression was used to verify that equivalent amounts of normal B lymphocyte cDNA had been loaded into the PCR reaction (lanes 1, 4, 7, and 10).



is a result of cellular activation. Induction of *trk b* expression by stimulation with the combination of polyclonal activating agents CD40L, IL2, and IL4 also suggests that expression is a result of activation rather than transformation. In support of this hypothesis, other investigators have shown that p75^{NGFR} is induced on cultured human melanocytes (Peacocke et al, 1988), and Trk A is similarly induced on KLH-activated T-cell clones (Ehrhard et al, 1994).

The function of mediating "cross-talk" between neuronal and immune cells has been proposed for NGF (Thorpe Perez-Polo, 1987; Ehrhard et al, 1993). This current study, demonstrating inducibility of *trk b* expression in B lymphocytes, suggests a specific role for BDNF and/or NT-4/5 in modulating the immune response within the nervous system. Because BDNF is only expressed locally within the central nervous system (CNS), this provides a potential mechanism by which the function of activated B lymphocytes might be modulated after entry into the CNS. Alternatively, up-regulation of expression of a growth factor receptor after transformation might provide a basis for B lymphocyte mitogenesis in CNS lymphomas. Finally, therapeutic trials have been initiated in which BDNF is used to treat motor neuron disease. Lymphocytes (in circulation, bone marrow, and spleen) are being exposed to high levels of the growth factor. It has been assumed that specific neuronal growth factors will not have stimulatory or mitogenic effects on non-neuronal cells. It is possible that this assumption may not be correct and patients in therapeutic trials should be monitored for potential adverse effects resulting from unexpected stimulation of B lymphocytes.

Acknowledgments

The assistance and advice of Dr. Diane F. Jelinek and Kjersti Aagaard-Tillery in the purification of B lymphocytes and of Ms. Diane M. Klein in EBV transformation is sincerely appreciated. The expert secretarial assistance of Ms. Linda A. Goldbeck in preparation and proofreading of the manuscript is appreciated. Supported by a research grant (NS 29769) from NIH.

REFERENCES

- Barbacid M. The Trk family of neurotrophin receptors. *J Neurobiol* 1994;25:1386–1403.
- Ehrhard PB, Erb P, et al. Expression of nerve growth factor and nerve growth factor receptor tyrosine kinase Trk in activated CD4-positive T-cell clones. *Proc Natl Acad Sci USA* 1993;90:10984–10988.
- Ehrhard PB, Erb P, et al. Expression of functional trk tyrosine kinase receptors after T cell activation. *J Immunol* 1994;152:2705–2709.
- Galili U, Schlesinger M. The formation of stable E rosettes after neuraminidase treatment of either human peripheral blood lymphocytes or of sheep red blood cells. *J Immunol* 1974;112:1628–1634.
- Jelinek DF, Lipsky PE. The roles of T cell factors in activation, cell cycle progression, and differentiation of human B cells. *J Immunol* 1985;134:1690–1701.
- Klein G. Epstein-Barr virus strategy in normal and neoplastic B cells. *Cell* 1994;77:791–793.
- Korsching S. The neurotrophic factor concept: a reexamination. *J Neurosci* 1993;13:2739–2748.
- Meakin SO, Shooter EM. The nerve growth factor family of receptors. *Trends Neurosci* 1992;15:323–331.
- Neitzel H. A routine method for the establishment of permanent growing lymphoblastoid cell lines. *Hum Genet* 1986;73:320–326.
- Otten U, Ehrhard P, et al. Nerve growth factor induces growth and differentiation of human B lymphocytes. *Proc Natl Acad Sci USA* 1989;86:10059–10063.
- Peacocke M, Yaar M, et al. Induction of nerve growth factor receptors on cultured human melanocytes. *Proc Natl Acad Sci USA* 1988;85:5282–5286.
- Rosenberg SA, Lipsky PE. Monocyte dependence of pokeweed mitogen-induced differentiation of immunoglobulin-secreting cells from human peripheral blood mononuclear cells. *J Immunol* 1979;122:926–931.
- Schenone A, Gill JS, et al. Expression of high- and low-affinity neurotrophin receptors on human transformed B lymphocytes. *J Neuroimmunol* 1996 (in press).
- Thiele DL, Kurosaka M, et al. Phenotype of the accessory cell necessary for mitogen-stimulated T and B cell responses in human peripheral blood: delineation by its sensitivity to the lysosomotropic agent, L-leucine methyl ester. *J Immunol* 1983;131:2282–2290.
- Thorpe LW, Perez-Polo JR. The influence of nerve growth factor on the in vitro proliferative response of rat spleen lymphocytes. *J Neurosci Res* 1987;18:134–139.

EDITOR

Keith H. Chiappa, M.D.

ASSOCIATE EDITOR

Didier Cros, M.D.

ELECTRONIC MAIL

chiappa@helix.mgh.harvard.edu

Journal of Contemporary Neurology is a peer-reviewed and electronically published scholarly journal that covers a broad scope of topics encompassing clinical and basic topics of human neurology, neurosciences and related fields.

EDITORIAL BOARD

Robert Ackerman
Massachusetts General Hospital, Boston

Barry Arnason
University of Chicago

Flint Beal
Massachusetts General Hospital, Boston

James Bernat
*Dartmouth-Hitchcock Medical Center,
New Hampshire*

Julien Bogousslavsky
CHU Vaudois, Lausanne

Robert Brown
Massachusetts General Hospital, Boston

David Burke
Prince of Wales Medical Research Institute, Sydney

David Caplan
Massachusetts General Hospital, Boston

Gregory Cascino
Mayo Clinic, Rochester

Phillip Chance
The Children's Hospital of Philadelphia, Philadelphia

Thomas Chase
NINDS, National Institutes of Health, Bethesda

David Cornblath
Johns Hopkins Hospital, Baltimore

F Michael Cutrer
Massachusetts General Hospital, Boston

David Dawson
Brockton VA Medical Center, Massachusetts

Paul Delwaide
Hôpital de la Citadelle, Liege

John Donoghue
Brown University, Providence

Richard Frith
Auckland Hospital, New Zealand

Myron Ginsberg
University of Miami School of Medicine

Douglas Goodin
University of California, San Francisco

James Grotta
University of Texas Medical School, Houston

James Gusella
Massachusetts General Hospital, Boston

John Halperin
*North Shore University Hospital / Cornell
University Medical College*

Stephen Hauser
University of California, San Francisco

E. Tessa Hedley-White
Massachusetts General Hospital, Boston

Kenneth Heilman
University of Florida, Gainesville

Daniel Hoch
Massachusetts General Hospital, Boston

Fred Hochberg
Massachusetts General Hospital, Boston

John Hoffman
Emory University, Atlanta

Gregory Holmes
Children's Hospital Boston

Bruce Jenkins
Massachusetts General Hospital, Boston

Ryuji Kaji
Kyoto University Hospital

Carlos Kase
Boston University School of Medicine, Boston

J. Philip Kistler
Massachusetts General Hospital, Boston

Jean-Marc Léger
La Salpêtrière, Paris

Simmons Lessell
Massachusetts Eye and Ear Infirmary, Boston

Ronald Lesser
Johns Hopkins Hospital, Baltimore

David Levine
New York University Medical Center

Ira Lott
University of California, Irvine

Phillip Low
Mayo Clinic, Rochester

Richard Macdonell
Austin Hospital, Victoria, Australia

Joseph Masdeu
St. Vincent's Hospital, New York

Kerry R. Mills
Radcliffe Infirmary, Oxford

José Ochoa
Good Samaritan Hospital, Portland

Barry Oken
Oregon Health Sciences University, Portland

John Penney
Massachusetts General Hospital, Boston

Karlheinz Reiners
Bayerische Julius-Maximilians-Universität, Würzburg

Allen Roses
Duke University Medical Center, Durham

Thomas Sabin
Boston City Hospital, Boston

Raman Sankar
University of California at Los Angeles

Joan Santamaria
Hospital Clinic Provincial de Barcelona

Kenneth Tyler
University of Colorado Health Science Center, Denver

Francois Viallet
CH Aix-en-Provence

Joseph Volpe
Children's Hospital, Boston

Michael Wall
University of Iowa, Iowa City

Stephen Waxman
Yale University, New Haven

Wigbert Wiederholt
University of California, San Diego

Eelco Wijdicks
Mayo Clinic, Rochester

Clayton Wiley
University of California, San Diego

Anthony Windebank
Mayo Clinic, Rochester

Shirley Wray
Massachusetts General Hospital, Boston

Anne Young
Massachusetts General Hospital, Boston

Robert Young
University of California, Irvine